2021.08.11
I-Mab today announced positive interim data from its U.S. phase 2/3 study of plonmarlimab for the treatment of cytokine release syndrome in patients with severe COVID-19.
2021.07.30
I-Mab today announced that the U.S. FDA has cleared the IND submission for Protollin, an investigational drug to treat Alzheimer’s disease, enabling a Phase 1 clinical trial to be initiated.
2021.07.29
I-Mab today announced that its Board of Directors has authorized a renewed stock repurchase program.
2021.07.28
I-Mab today announced that an IND application for the initiation of a phase 2 clinical trial of efineptakin alfa in combination with anti-PD-1 antibody in patients with advanced solid tumors has been accepted by the CDE of the China NMPA.
2021.07.27
The Board of Directors of I-Mab approved a preliminary proposal for the potential dual listing of the Company’s newly issued shares on the Science and Technology Innovation Board of the Shanghai Stock Exchange.
2021.07.09
I-Mab today announced the signing of two new collaborations with emerging biotech companies in China to strengthen its next-generation innovation pipeline.
2021.07.01
I-Mab today announced multiple advancements in its 4-1BB bispecific antibody portfolio.
2021.06.30
I-Mab today announced that it was ranked among the top companies by leading global financial publication Institutional Investor in both the “Honored Companies” and “Best CFO” categories, according to its 2021 All-Asia Executive Team survey.
2021.06.29
I-Mab today announced its participation in the following conference in July.
2021.06.25
I-Mab today announced that the Center for Drug Evaluation of the China NMPA has approved the IND application to initiate a phase 1b trial of felzartamab, a CD38 antibody, in patients with SLE.